TICKERNOMICS Sign up
Last Update: 2024-03-28 02:12:16
Alector Inc. ( ALEC ) https://www.alector.com
5.96USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-4.33%
ALEC
SPY
32.74%
-63.55%
ALEC
SPY
92.93%
-68.16%
ALEC
SPY
224.41%
ALEC
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
507.58
59.60
0.35
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-3.59
5.27
3.78
-34.40
0.00
-0.41
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-555.31
100.00
-160.50
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-239.71
-34.12
0.00
Other Earnings and Cash Flow Stats:
Alector Inc. ( ALEC ) Net Income TTM ($MM) is -188.91
Alector Inc. ( ALEC ) Operating Income TTM ($MM) is -203.88
Alector Inc. ( ALEC ) Owners' Earnings Annual ($MM) is -189.31
Alector Inc. ( ALEC ) Current Price to Owners' Earnings ratio is -2.67
Alector Inc. ( ALEC ) EBITDA TTM ($MM) is -195.38
Alector Inc. ( ALEC ) EBITDA Margin is -160.50%
Capital Allocation:
Alector Inc. ( ALEC ) has paid 0.00 dividends per share and bought back -2.412106 million shares in the past 12 months
Alector Inc. ( ALEC ) has reduced its debt by 4.409 million USD in the last 12 months
Capital Structure:
Alector Inc. ( ALEC ) Interest-bearing Debt ($MM) as of last quarter is 38
Alector Inc. ( ALEC ) Annual Working Capital Investments ($MM) are -25
Alector Inc. ( ALEC ) Book Value ($MM) as of last quarter is 134
Alector Inc. ( ALEC ) Debt/Capital as of last quarter is 29%
Other Balance Sheet Stats:
Alector Inc. ( ALEC ) has 74 million in cash on hand as of last quarter
Alector Inc. ( ALEC ) has 177 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Alector Inc. ( ALEC ) has 84 common shares outstanding as of last quarter
Alector Inc. ( ALEC ) has 0 million USD of preferred stock value
Academic Scores:
Alector Inc. ( ALEC ) Altman Z-Score is -0.90 as of last quarter
Alector Inc. ( ALEC ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Alector Inc. ( ALEC ) largest shareholder is owning shares at 0.00 ($MM) value
Marc Grasso(an insider) Sold 5716 shares of Alector Inc. ( ALEC ) for the amount of $39554.72 on 2024-03-04
10.75% of Alector Inc. ( ALEC ) is held by insiders, and 85.52% is held by institutions
Alector Inc. ( ALEC ) went public on 2019-02-07
Other Alector Inc. ( ALEC ) financial metrics:
FCF:-196.87
Unlevered Free Cash Flow:-86.35
EPS:-2.10
Operating Margin:-555.31
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-132.60
Beta:0.00
Buffet's Owners Earnings:-189.31
Price to Owner's Earnings:-2.67
About Alector Inc. ( ALEC ) :
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.